Skip to main content

Table 1 Patient, disease, and treatment characteristics stratified by BRCA status (n = 61)

From: Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women

Characteristics   BRCA mutant n = 25 (41%) BRCA wild type n = 36 (59%) P-Value*
N (Frequency) N (Frequency)
Age at diagnosis
Median (IQR)   50 (43–56) 55 (46–66) 0.13
Age ≤ 50   14 (56) 15 (41.7) 0.27
Positive personal history of cancer   5 (20) 1 (2.9) 0.04
Positive family history of cancer   7 (28) 2 (5.6) 0.02
Presence of comorbidities*   19 (76) 24 (66.7) 0.43
Histology High-grade serous 25 (100) 35 (97.1) 0.39
  Endometrioid   1 (2.9)  
High grade FIGO stage   25 (100) 34 (94.4) 0.48
  Stage 1 6 3 0.65
  IA 2 0  
  IB 2 1  
  IC 2 2  
  Stage 2 1 4  
  IIA 1 1  
  IIB 0 3  
  Stage 3 15 (58) 21 (55)  
  IIIA 0 2  
  IIIB 1 2  
  IIIC 14 17  
  Stage 4 4 10  
High CA125 (> 35)   20 (80) 26 (72.2) 0.46
Initial management PDS 12 (48) 18 (50) 0.87
  NAC 13 (52) 18 (50)  
No. of lines, median (IQR)   3 (1–5) 3 (2–4.75) 0.79
Lines of treatment
First line (n = 61)   (n = 25) (n = 18)  
PBC Non PBC   100% 100% 0.26
Second line (n = 49)   (n = 18) (n = 31)  
PBC   88.9 83.4 0.79
Non PBC   11.1 16.6  
Third line (n = 39)   (n = 13) (n = 26)  
PBC   73.1 64 0.42
Non PBC   26.9 36  
Fourth line (n = 23)   (n = 10) (n = 13)  
PBC   50% 23.1% 0.38
Non PBC   50% 76.9%  
Fifth line (n = 13)   (n = 7) (n = 5)  
PBC   0.68
Non PBC   100% 100%  
  1. Categorical values were compared with the Chi-square test or Fisher’s exact test, and continuous values were described as the median with interquartile range (IQR) and compared using the Mann-Whitney U test
  2. Comorbidities: hypertension, DM, hypothyroidism, bronchial asthma, dyslipidemia, or osteoarthritis. PBC; platinum-based chemotherapy; non PBC, non-platinum-based chemotherapy (Paclitaxel, Liposomal doxorubicin, Etoposide, Gemcitabine, Topotecan, Letrozole, Tamoxifen)